ResearcherChulalongkorn UniversityActive in the last 2 years
Thanawat Luangsukrerk
Matched on ORCID iD 0000-0002-5804-3068; OpenAlex author ID A5065139255. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2023: 1 paper · 2024: 1 paper · 2025: 1 paper
Papers 3
- One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequency ablation. Last author DOI 10.1016/j.gie.2025.06.008↗
- A prospective comparative trial to determine the optimal number of EUS-guided fineneedle passes for successful organoid creation in pancreatic ductal adenocarc… Co-author DOI 10.1097/eus.0000000000000098↗
- EUS-guided radiofrequency ablation plus chemotherapy versus chemotherapy alone for pancreatic cancer (ERAP): An observational open-label pilot study. Co-author DOI 10.1097/eus.0000000000000003↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Pradermchai Kongkam · 3 shared papers, 2023–2025 · strength 0.58
- Paper One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequenc… DOI 10.1016/j.gie.2025.06.008↗
- Paper A prospective comparative trial to determine the optimal number of EUS-guided fineneedle passes for successful organoid… DOI 10.1097/eus.0000000000000098↗
- Paper EUS-guided radiofrequency ablation plus chemotherapy versus chemotherapy alone for pancreatic cancer (ERAP): An observa… DOI 10.1097/eus.0000000000000003↗
- Rungsun Rerknimitr · 3 shared papers, 2023–2025 · strength 0.58
- Paper One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequenc… DOI 10.1016/j.gie.2025.06.008↗
- Paper A prospective comparative trial to determine the optimal number of EUS-guided fineneedle passes for successful organoid… DOI 10.1097/eus.0000000000000098↗
- Paper EUS-guided radiofrequency ablation plus chemotherapy versus chemotherapy alone for pancreatic cancer (ERAP): An observa… DOI 10.1097/eus.0000000000000003↗
- Pinit Kullavanijaya · 2 shared papers, 2023–2025 · strength 0.37
- Paper One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequenc… DOI 10.1016/j.gie.2025.06.008↗
- Paper EUS-guided radiofrequency ablation plus chemotherapy versus chemotherapy alone for pancreatic cancer (ERAP): An observa… DOI 10.1097/eus.0000000000000003↗
- Phonthep Angsuwatcharakon · 2 shared papers, 2023–2025 · strength 0.37
- Paper One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequenc… DOI 10.1016/j.gie.2025.06.008↗
- Paper EUS-guided radiofrequency ablation plus chemotherapy versus chemotherapy alone for pancreatic cancer (ERAP): An observa… DOI 10.1097/eus.0000000000000003↗
- Kasenee Tiankanon · 2 shared papers, 2023–2025 · strength 0.37
- Paper One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequenc… DOI 10.1016/j.gie.2025.06.008↗
- Paper EUS-guided radiofrequency ablation plus chemotherapy versus chemotherapy alone for pancreatic cancer (ERAP): An observa… DOI 10.1097/eus.0000000000000003↗
- Parit Mekaroonkamol · 1 shared paper, 2025 · strength 0.21
- Nipan Israsena · 1 shared paper, 2024 · strength 0.21
- Dong Wan Seo · 1 shared paper, 2023 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.